The 995-Node
Intelligence Forest
The world's most comprehensive, source-verified resource for autonomous AI agents. Every node is cryptographically signed, RAG-optimized, and gated via L402 settlement protocols.
Neural Discovery Search
bidda.com / authority / sovereign-forest
SHA-256_INTEGRITY_AUDIT_PASSED
AI Model Valuation (IAS 38)
"IAS 38 Intangible Assets, issued by the IASB, governs the recognition, measurement, and disclosure of intangible assets including internally developed AI models, training datasets, and software. An intangible asset must meet strict recognition criteria: identifiability, control, and probable future economic benefit. Development-phase AI expenditure may be capitalized only after technical feasibility is established under all six IAS 38.57 criteria, while research-phase costs must be expensed immediately. Failure to correctly distinguish research from development phases, or to apply impairment testing under IAS 36, results in materially misstated financial statements and potential regulatory action by securities authorities."
Technical ID
accounting-ias-38
Digital Asset Fair Value (IFRS 13)
"IFRS 13 Fair Value Measurement establishes a single framework for measuring fair value across all IFRS standards that require or permit fair value measurement, including digital assets, AI-tokenized instruments, and crypto holdings. Fair value is defined as the exit price in an orderly transaction between market participants at the measurement date. Entities must classify inputs into a three-level hierarchy (Level 1: quoted prices in active markets; Level 2: observable inputs; Level 3: unobservable inputs) and maximize use of observable inputs. Digital and AI-linked assets with limited trading history frequently fall into Level 3, requiring robust valuation models and extensive disclosures; inadequate classification or disclosure triggers audit qualifications and securities regulator scrutiny."
Technical ID
accounting-ifr-13
Engineers Ethics (ACEC)
"The American Council of Engineering Companies (ACEC) Code of Ethics establishes the binding professional obligations for licensed engineers and consulting firms. Engineers must hold paramount the safety, health, and welfare of the public above all client or employer interests. Core obligations include qualifications-based fee competition (Brooks Act compliance), professional seal authorization, conflict-of-interest disclosure, errors and omissions insurance, and continuing professional education. Violations expose firms to license revocation, civil liability, and federal debarment."
Technical ID
acec-ethics-eng
ADA (Employment Title I)
"The Americans with Disabilities Act Title I (42 U.S.C. §12101–12117), as amended by the ADA Amendments Act of 2008 (ADAAA), is the primary U.S. federal law prohibiting employment discrimination against qualified individuals with disabilities. Covered employers with 15 or more employees must provide reasonable accommodations unless doing so causes undue hardship. Title I restricts all medical inquiries to post-conditional-offer only, mandates initiation of the interactive process upon disclosure of a disabling limitation, and requires accessible employment technology at WCAG 2.1 AA minimum. The EEOC enforces Title I through administrative charges; violations expose employers to back pay, compensatory and punitive damages, and injunctive relief requiring policy and structural changes."
Technical ID
ada-employment-title-1
ADA (Hospitality Accessibility)
"ADA Title III (42 U.S.C. §12181–12189) requires all places of public accommodation — including hotels, motels, restaurants, bars, and food service establishments — to provide equal access to individuals with disabilities. New construction and alterations commenced after January 26, 1992 must fully comply with the 2010 ADA Standards for Accessible Design. Existing facilities must remove architectural barriers where readily achievable. Hotels must provide a regulated percentage of accessible guest rooms, van-accessible parking at prescribed ratios, accessible routes of 36-inch minimum clear width, pool lifts for pools exceeding 300 linear feet of pool wall, and visual communication features for guests with hearing impairments. DOJ enforces Title III through civil investigations and pattern-or-practice suits; private plaintiffs may sue for injunctive relief and attorney fees. Non-compliant operators face structural modification orders and potential damages in states with enhanced state accessibility laws."
Technical ID
ada-hospitality-access
Agent Budgetary Controls & Ceiling Checks
"Agentized financial controls (Action Boundaries) restrict an autonomous agent's spending power per session, task, or API call to prevent catastrophic loss or unbounded consumption. A properly implemented budget cap architecture requires: a durable spend counter initialized at agent boot, pre-call ceiling checks before every API invocation, fleet-level daily aggregation across all sessions, hard stops on breach with no retry path, mandatory human approval gates for high-value actions, full audit logging of every spend event, and MFA-gated emergency override procedures. Absent these controls, autonomous agents can exhaust allocated compute budgets, incur unexpected cloud costs, or trigger runaway API consumption within a single malformed task."
Technical ID
agent-budget-cap
Agent Emergency Stop (Kill-Switch) Design Patterns
"An AI Agent Kill-Switch is a deterministic safety mechanism designed to immediately terminate or throttle an autonomous agent's execution if it exceeds predefined behavioral, financial, or operational boundaries."
Technical ID
agent-kill-switch
Multi-Agent Collision Resolution
"Multi-agent collision logic provides deterministic protocols for resolving conflicts when two or more autonomous AI agents simultaneously attempt to access the same resource, modify the same shared state, execute contradictory actions, or pursue incompatible goal trajectories within a swarm or orchestration framework. Without collision resolution, multi-agent systems produce race conditions, data corruption, deadlocks, and cascading failures that are difficult to audit or remediate. The resolution framework draws from distributed systems theory — consensus algorithms, vector clocks, conflict-free replicated data types (CRDTs), and resource arbitration — as well as emerging agentic safety standards. Properly implemented collision logic ensures predictable, auditable outcomes and maintains system safety invariants even when individual agents operate concurrently and autonomously."
Technical ID
ai-agent-collision-logic
AI-IP: Guidance on Authorship
"The US Copyright Office's AI Policy Statement (February 2023) and subsequent guidance (March 2023) establish that copyright protection requires human authorship — purely AI-generated content without human creative control is not copyrightable in the United States. Works involving AI assistance may receive copyright protection for the human-authored elements, but only if a human author made sufficient creative choices that were expressed in the final output. The EU, UK, and other jurisdictions take varying positions, with the UK's Computer Generated Works doctrine providing limited protection for AI outputs. Misrepresenting AI-generated content as human-authored to obtain copyright registration constitutes fraud; failure to disclose AI involvement in patent applications may similarly invalidate those applications."
Technical ID
ai-ip-copyright
AICPA Code of Ethics
"The AICPA Code of Professional Conduct (ET §0.300) establishes binding ethical standards for Certified Public Accountants in public practice and business. The Code requires CPAs to maintain independence in all attest engagements — any direct or material indirect financial interest in an audit client creates an impairment with no de minimis exception. The Conceptual Framework (ET §1.010.010) mandates evaluation of five threat categories (self-interest, self-review, advocacy, familiarity, and intimidation) and application of safeguards before accepting or continuing any engagement. Key operational requirements include: 40 hours of continuing professional education annually, 7-year documentation retention under PCAOB Rule 4003, engagement quality review by a second partner for all public company audits, prohibition on management functions and bookkeeping for audit clients under SOX §201, and confidentiality breach notification within 24 hours. Violations expose CPAs to AICPA Ethics Division investigation, state board disciplinary action, license revocation, and SEC or PCAOB enforcement proceedings for registered firms."
Technical ID
aicpa-code-ethics
Responsible Alcohol Service
"Responsible alcohol service standards govern the legal and operational obligations of licensed on-premise alcohol retailers — bars, restaurants, hotels, event venues, and stadiums — to prevent service to minors and visibly intoxicated patrons. The National Minimum Drinking Age Act (23 U.S.C. §158) mandates a minimum legal drinking age of 21 in all U.S. states; service to minors exposes licensees to criminal liability, license revocation, and civil dram shop liability. State Dram Shop Acts impose third-party tort liability on servers who provide alcohol to visibly intoxicated persons who subsequently cause injury. Compliance requires: mandatory server certification through programs such as TIPS (Training for Intervention ProcedureS) or ServSafe Alcohol, documented ID verification procedures with a check-for-anyone-appearing-under-30 standard, written protocols for identifying signs of intoxication and executing patron cutoff, incident log maintenance, and manager override authorization for disputed service decisions. Licensees failing to enforce responsible service standards face ABC license suspension, criminal prosecution of servers, and civil judgments in dram shop actions that have exceeded $1 million in multiple U.S. jurisdictions."
Technical ID
alcohol-service-std
Amazon Ads (Policy)
"Compliance with this node ensures adherence to a comprehensive framework governing Amazon advertising, rooted in both platform policy and federal law. All advertising creative must meet stringent content requirements outlined in the Amazon Advertising Guidelines and Acceptance Policies, which mandate a minimum image longest side of 1000 pixels while strictly disallowing text on any main product image. Accompanying custom text fields are constrained to a maximum length of 50 characters. In alignment with guidance from FTC .com Disclosures, a sponsored disclosure is unequivocally required to maintain transparency with consumers. The node prohibits practices that could mislead consumers, reflecting the Lanham Act's general prohibition against false descriptions of fact in commerce. Consequently, deceptive pricing claims are disallowed, and any unsubstantiated claims are similarly forbidden, a rule further supported by the FTC Guides Concerning the Use of Endorsements and Testimonials regarding assertions like 'bestseller.' To protect platform integrity per the Amazon Seller Central Policy, off-platform redirection is not permitted, and a direct landing page ASIN match is mandated for all ad clicks. Intellectual property protections are enforced through mandatory brand registry verification as stipulated by the Amazon Brand Registry Terms of Use, a standard which also underpins the policy to prohibit competitor brand disparagement. Finally, all advertisements must utilize a supported marketplace language and avoid any restricted or prohibited product categories."
Technical ID
amazon-sponsored-ads-policy
China CAC Generative AI & Algorithmic Registry
"Mandatory security assessment and algorithmic filing requirements for public-facing generative AI services and agents operating within or interacting with mainland China."
Technical ID
cn-cac-genai-measures
DICOM Imaging Standard
"DICOM (Digital Imaging and Communications in Medicine) is the international standard for medical imaging and related information. It specifies the network protocols for image exchange (PACS/RIS integration), the media format for storage (PS3.10), and the web services (WADO-RS) for image retrieval across the healthcare enterprise."
Technical ID
dicom-imaging-standard
Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use (CTR), focusing on AI-Assisted Clinical Trials and Data Management
"This regulation harmonizes the processes for clinical trials in the EU, requiring that all electronic systems, including AI/ML models, used for generating, processing, or storing trial data be validated, secure, and maintain a complete audit trail to ensure data integrity and reliability (Article 52). It mandates the use of the centralized EU Portal and EU Database (CTIS) for all trial submissions and communications."
Technical ID
eu-clinical-trials-regulation-2022
Regulation on the European Health Data Space (EHDS)
"The EHDS Regulation establishes a framework for the primary use (patient care) and secondary use (research, innovation, policy-making) of electronic health data across the EU. It mandates interoperability for Electronic Health Record (EHR) systems and creates a secure infrastructure for data access, requiring data holders to make specific categories of data available for secondary use through Health Data Access Bodies (HDABs) under strict conditions (Chapter IV, Article 33)."
Technical ID
eu-health-data-space-2024
EU IVDR 2017/746 (Diagnostics)
"EU Regulation 2017/746 (In-Vitro Diagnostic Medical Device Regulation - IVDR) is the primary framework for diagnostic devices in the European Union. It replaces the previous 98/79/EC directive and dramatically increases the oversight of IVDs, requiring nearly 80% of devices to undergo notified body audit (vs. 20% previously)."
Technical ID
eu-ivdr-2017-746
EU MDR 2017/745 (Devices)
"EU Regulation 2017/745 (Medical Device Regulation - MDR) is the primary framework for medical device compliance in the European Union. It replaces the previous MDD/AIMDD directives, introducing more rigorous requirements for pre-market clinical evaluation, post-market surveillance (PMS), and traceability through the UDI system."
Technical ID
eu-mdr-2017-745
MDCG 2019-11 Guidance on Qualification and Classification of Software in Regulation (EU) 2017/745 – MDR and Regulation (EU) 2017/746 – IVDR
"This guidance provides criteria for qualifying software as a Medical Device (MDSW) or In Vitro Diagnostic (IVD) Medical Device and outlines the risk-based classification rules under EU MDR and IVDR. Manufacturers must apply MDR Annex VIII, Rule 11, which classifies software based on the significance of the information provided and the healthcare situation, to determine if their AI/ML software is Class I, IIa, IIb, or III."
Technical ID
eu-medical-device-ai-guidance-2021
FDA 21 CFR Part 11 (Records)
"FDA 21 CFR Part 11 establishes the U.S. requirements for electronic records and electronic signatures. It defines the criteria under which the FDA considers electronic records, electronic signatures, and handwritten signatures executed to electronic records to be trustworthy, reliable, and generally equivalent to paper records."
Technical ID
fda-21-cfr-part-11-records
FDA 21 CFR Part 820 (QSR)
"FDA 21 CFR Part 820 is the Quality System Regulation (QSR) governing the manufacture and design of medical devices in the United States. It requires medical device manufacturers to establish a quality system to ensure that their products consistently meet applicable requirements and specifications."
Technical ID
fda-21-cfr-part-820-qsr
Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan
"This Action Plan outlines the U.S. Food and Drug Administration's (FDA) multi-pronged approach to advance its oversight of Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD). Developed in response to stakeholder feedback on a 2019 discussion paper, the plan applies to medical device manufacturers utilizing AI/ML technologies. Its core objective is to establish a total product lifecycle-based regulatory oversight framework that allows SaMD to learn from real-world use and improve its performance while ensuring safety and effectiveness. A central component of this framework is the "Predetermined Change Control Plan" to be included in premarket submissions. This plan consists of two key elements: the "SaMD Pre-Specifications" (SPS), which describe the anticipated modifications, and the "Algorithm Change Protocol" (ACP), which details the methodology for implementing changes in a controlled manner that manages patient risks. The document details a five-part action plan: (1) issuing a Draft Guidance on the Predetermined Change Control Plan; (2) encouraging the harmonization of Good Machine Learning Practice (GMLP); (3) promoting a patient-centered approach that incorporates transparency to users through device labeling; (4) supporting regulatory science to develop methods for addressing algorithm bias and robustness; and (5) advancing real-world performance monitoring through pilot programs with stakeholders."
Technical ID
fda-ai-ml-samd-action-plan
Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan
"This Action Plan from the U.S. Food & Drug Administration (FDA) outlines a five-part strategy to regulate Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD). Developed in response to stakeholder feedback on a 2019 discussion paper, the plan aims to ensure that AI/ML-based SaMD is safe and effective while supporting innovation. The core of the proposed framework is a "Predetermined Change Control Plan" submitted by manufacturers, which includes the "SaMD Pre-Specifications" (SPS) detailing anticipated modifications and an "Algorithm Change Protocol" (ACP) explaining how changes will be implemented and validated. The plan applies to medical device manufacturers utilizing AI/ML technologies in SaMD. The five key actions are: 1) updating the regulatory framework, including issuing draft guidance on the Predetermined Change Control Plan; 2) encouraging the harmonization of Good Machine Learning Practices (GMLP); 3) promoting a patient-centered approach that incorporates transparency for users; 4) supporting regulatory science to address algorithm bias and robustness; and 5) advancing Real-World Performance (RWP) monitoring through pilot programs. This approach is intended to provide a total product lifecycle-based regulatory oversight, enabling the FDA to monitor software from premarket development through postmarket performance."
Technical ID
fda-aiml-samd-action-plan
FDA Clinical Decision Software
"The FDA Guidance on Clinical Decision Support (CDS) Software (2022) provides the criteria under which software functions are NOT considered medical devices under Section 520(o)(1)(E) of the FD&C Act. It focus on ensuring that the healthcare professional (HCP) can independently review the basis for the software's recommendations to ensure patient safety."
Technical ID
fda-clinical-decision-support
Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions
"With the increasing integration of wireless, Internet- and network-connected capabilities, the need for robust cybersecurity controls to ensure medical device safety and effectiveness has become more important. Cybersecurity threats to the healthcare sector have become more frequent and severe, with incidents rendering medical devices and hospital networks inoperable. This guidance applies to devices with cybersecurity considerations, including those with software or programmable logic, across various premarket submission types such as 510(k), PMA, DeNovo, IDE, and HDE. It outlines the Food and Drug Administration's (FDA) recommendations for the cybersecurity information to be submitted to demonstrate a reasonable assurance of safety and effectiveness. The guidance emphasizes that cybersecurity is a shared responsibility and a key part of device safety and the Quality Management System Regulation (QMSR). It encourages manufacturers to adopt a Secure Product Development Framework (SPDF) to manage cybersecurity risks throughout the total product lifecycle (TPLC). For devices that meet the definition of a 'cyber device' under section 524B of the FD&C Act, sponsors are required to submit specific information. This includes a plan to monitor, identify, and address postmarket cybersecurity vulnerabilities; processes to provide reasonable assurance of device cybersecurity; and a Software Bill of Materials (SBOM) for all software components."
Technical ID
fda-cybersecurity-medical-devices-premarket
Guidance for Industry Electronic Source Data in Clinical Investigations
"This guidance provides recommendations to sponsors, Contract Research Organizations (CROs), clinical investigators, and others involved in the capture, review, and retention of electronic source data in FDA-regulated clinical investigations. To streamline and modernize clinical investigations, the guidance promotes capturing source data in electronic form, intending to assist in ensuring the reliability, quality, integrity, and traceability of data from the electronic source to electronic regulatory submission. The core recommendations address the identification and specification of authorized source data originators; the creation of data element identifiers to facilitate audit trail examination; methods to capture source data into an electronic case report form (eCRF) either manually or electronically; and the responsibilities of clinical investigators regarding the review, signature, and retention of electronic data. The guidance emphasizes that source data must be attributable, legible, contemporaneous, original, and accurate (ALCOA) and meet all regulatory requirements for recordkeeping. It is intended to be used in conjunction with other FDA guidance on computerized systems and regulations on electronic records and signatures."
Technical ID
fda-electronic-source-data
Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions
"This FDA guidance enables manufacturers of AI/ML-based medical devices to pre-authorize a set of planned modifications within a Predetermined Change Control Plan (PCCP) as part of a premarket submission (510(k), De Novo, PMA), allowing for device evolution without requiring a new submission for each change covered by the approved plan."
Technical ID
fda-predetermined-change-control-2024
FRAMEWORK FOR FDA’S REAL WORLD EVIDENCE PROGRAM
"Pursuant to the 21st Century Cures Act, which added section 505F to the Federal Food, Drug, and Cosmetic Act (FD&C Act), the Food and Drug Administration (FDA) has created a framework for evaluating the potential use of real-world evidence (RWE). This framework is designed to help support the approval of a new indication for a drug already approved under section 505(c) of the FD&C Act, or to help support or satisfy drug postapproval study requirements. The framework applies to drugs and biological products but does not cover medical devices. Real-World Data (RWD) are defined as data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources, such as electronic health records (EHRs) and medical claims. RWE is the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of RWD. The core of the FDA's evaluation approach under this framework consists of a three-part assessment for any RWE submission. The considerations are: 1. Whether the RWD are fit for use, which involves assessing data reliability (data accrual and data assurance) and relevance. 2. Whether the trial or study design used to generate RWE can provide adequate scientific evidence to answer the regulatory question. 3. Whether the study conduct meets FDA regulatory requirements, such as for study monitoring and data collection. The FDA's RWE Program is multifaceted, involving demonstration projects, stakeholder engagement, internal processes for senior leadership input, and the development of guidance documents to assist developers."
Technical ID
fda-real-world-evidence-program
FDA Software as a Medical Device (SaMD) Risk Matrix
"A risk-based framework for classifying software intended for medical purposes independently of hardware, based on IMDRF categorizations and FDA safety standards."
Technical ID
fda-samd-risk
Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD)
"This FDA discussion paper outlines a Total Product Lifecycle (TPLC) approach for AI/ML-based medical software, proposing a Predetermined Change Control Plan (PCCP) that allows manufacturers to manage algorithm modifications without requiring a new premarket submission for every change, provided the changes stay within the approved plan's scope. This framework applies to manufacturers of AI/ML-based Software as a Medical Device (SaMD) seeking to leverage adaptive algorithms."
Technical ID
fda-software-as-medical-device-2019
GDPR: Health Data (Art. 9)
"GDPR Article 9 establishes a general prohibition on processing special categories of personal data, with 'data concerning health' (including mental health, genetic data, and biometric data used for identification) receiving the highest level of protection. Processing is only permitted under ten exhaustive exemptions including explicit consent, vital interests, medical purposes under professional secrecy, public health, and scientific research under appropriate safeguards. AI systems processing health data — including medical AI, diagnostic tools, health chatbots, and research analytics platforms — must identify a specific Article 9(2) exemption, implement appropriate technical and organizational measures, and in most cases conduct a Data Protection Impact Assessment (DPIA) under Article 35. Violations involving special category health data attract the highest GDPR fines: up to €20 million or 4% of global annual turnover under Article 83(5)."
Technical ID
gdpr-health-data
GDPR Health Data (EU)
"The EU GDPR 2016/679 (General Data Protection Regulation) classifies health data as a 'special category' of personal data. Article 9 generally prohibits the processing of such data unless a specific legal exemption is met, necessitating a high level of security and stricter compliance requirements compared to general personal data."
Technical ID
gdpr-health-data-compliance
Good Machine Learning Practice for Medical Device Development: Guiding Principles
"The U.S. Food and Drug Administration (FDA), Health Canada, and the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) have jointly identified 10 guiding principles that can inform the development of Good Machine Learning Practice (GMLP). These principles aim to promote safe, effective, and high-quality medical devices that use artificial intelligence and machine learning (AI/ML). AI/ML technologies have the potential to transform health care by deriving new insights from vast amounts of data, but they also present unique considerations due to their complexity and the iterative, data-driven nature of their development. These 10 guiding principles are intended to lay the foundation for developing GMLP that addresses the unique nature of these products and to cultivate future growth in this rapidly progressing field. They identify areas where international bodies could work to advance GMLP, including research, creating educational tools, international harmonization, and consensus standards. The principles may be used to adopt good practices from other sectors, tailor them for medical technology, or create new practices specific to the healthcare sector."
Technical ID
good-machine-learning-practice-medical-devices
Good Clinical Practice (GCP)
"Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve human subjects. Based on the ICH E6(R2) guideline, compliance provides public assurance that the rights, safety, and well-being of trial subjects are protected and that the clinical trial data are credible."
Technical ID
gxp-clinical-practice
Good Mfg Practice (GMP)
"Good Manufacturing Practice (GMP) (21 CFR Parts 210 and 211) is the primary U.S. and global standard for ensuring that pharmaceutical and medical device products are consistently produced and controlled according to high-quality standards. it is designed to minimize the risks involved in production that cannot be eliminated through testing the final product."
Technical ID
gxp-mfg-practice
HIPAA Breach Notification Rule
"A breach of unsecured protected health information, as defined under 45 CFR § 164.402, has been confirmed following a risk assessment that did not demonstrate a low probability of compromise. Given this event affects 500 individuals, immediate and specific notification obligations are triggered for the covered entity, which retains the burden of proof for compliance according to 45 CFR § 164.414. Pursuant to 45 CFR § 164.404, individual notifications must be issued without unreasonable delay and, at 60 days since discovery, are now due; the content of this notification must adhere to prescribed federal requirements. Concurrently, because the number of affected persons meets the threshold, 45 CFR § 164.408 requires immediate notice to the Secretary of Health and Human Services. This action is separate from the annual logging of smaller breaches. Furthermore, with 500 individuals affected within a single jurisdiction, compliance with 45 CFR § 164.406 is mandatory, necessitating notice to prominent media outlets serving the relevant State or locality within the same 60-day timeframe. These stringent timelines underscore the importance of prompt reporting from business associates to covered entities, a process governed by 45 CFR § 164.410 that enables downstream regulatory adherence."
Technical ID
hipaa-breach-notification
HIPAA Privacy Rule
"The HIPAA Privacy Rule establishes national standards governing the use and disclosure of protected health information (PHI) by covered entities and their business associates. General rules articulated within 45 CFR § 164.502 mandate the implementation of appropriate safeguards and require formal business associate agreements for any third-party handling PHI. A foundational principle is the minimum necessary standard, enforced pursuant to 45 CFR § 164.514, which limits PHI use or disclosure to the minimum required for a specific purpose. Specific authorizations from individuals are mandated under 45 CFR § 164.508 for certain uses, including nearly all marketing communications, while the unauthorized sale of PHI is strictly prohibited. The regulation further grants individuals significant rights over their health information. Covered entities must provide a clear Notice of Privacy Practices as specified in 45 CFR § 164.520. Individuals have a right to access their designated record set, with such provision required within a maximum of 30 days per 45 CFR § 164.524. An accounting of disclosures must also be furnished upon request within 60 days, according to 45 CFR § 164.528. Entities have up to 60 days to act upon an individual’s amendment request. Compliance requires appointing a privacy officer, conducting workforce training, and retaining all related documentation for a period of six years."
Technical ID
hipaa-privacy-rule
HIPAA Security Rule
"The HIPAA Security Rule (45 CFR Part 160 and Part 164) establishes U.S. national standards for the protection of Electronic Protected Health Information (ePHI). It focuses on ensure the confidentiality, integrity, and availability of ePHI through three pillars: Administrative, Physical, and Technical Safeguards."
Technical ID
hipaa-security-rule
Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009
"The HITECH Act strengthens HIPAA privacy and security rules by requiring public notification for breaches of unsecured Protected Health Information (PHI), increasing penalties for non-compliance, and promoting the adoption of certified Electronic Health Records (EHRs). It applies to all HIPAA Covered Entities and their Business Associates, with key breach notification requirements detailed in Section 13402."
Technical ID
hitech-act-2009
HL7 FHIR Interoperability (Release 4)
"Standardized RESTful API architecture for electronic health information exchange, using modular Resources to enable computable healthcare data across disparate systems."
Technical ID
hl7-fhir-interop
HL7 FHIR v4 (Interoperability)
"HL7 FHIR (Fast Healthcare Interoperability Resources) Release 4 is the global standard for electronic healthcare data exchange. It defines a set of 'Resources' that represent granular clinical and administrative data, accessible via a RESTful API to enable seamless interoperability between EHRs, mobile apps, and analytics platforms."
Technical ID
hl7-fhir-v4-interop
IEC 62304 (Medical Software)
"IEC 62304 is the international standard for medical device software lifecycle processes. It defines the framework of processes, activities, and tasks for the safe design and maintenance of medical software, regardless of whether the software is a standalone product (SaMD) or embedded within a hardware device."
Technical ID
iec-62304-medical-software
IEC 82304-1 (Health Software)
"IEC 82304-1:2016 is the international standard for general health software product safety. It is designed for software products that do not have dedicated hardware and are used in health environments (e.g., lifestyle, wellness, or administrative software), ensuring safety, reliability, and security across the product lifecycle."
Technical ID
iec-82304-1-health-software
IMDRF SaMD Risk Framework
"The IMDRF Software as a Medical Device (SaMD) Risk Categorization Framework provides a globally harmonized method for classifying the risk of independent medical software. It categorizes SaMD into four levels (I, II, III, IV) based on the criticality of the clinical situation and the impact of the information provided by the software on patient care."
Technical ID
imdrf-samd-risk-framework
India MeitY IT Rules (Synthetic Content Amendment)
"Mandatory disclosure, verification, and visual/audio labelling requirements for AI-generated synthetic content by Significant Social Media Intermediaries (SSMIs) operating in India."
Technical ID
in-meity-synthetic-content
ISMP Medication Safety
"The ISMP (Institute for Safe Medication Practices) Best Practices provide a set of consensus-based national standards for reducing medication errors in hospitals and healthcare settings. They focus on high-alert medications, 'Look-Alike/Sound-Alike' (LASA) drug nomenclature, and the implementation of error-reduction strategies across the medication-use process."
Technical ID
ismp-medication-safety
ISO 13485 (Medical QMS)
"ISO 13485:2016 is the global standard for Medical Device Quality Management Systems (QMS). It specifies requirements for a QMS where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer and applicable regulatory requirements."
Technical ID
iso-13485-medical-qms
Medical Quality (ISO 13485)
"ISO 13485:2016 is the internationally recognized Quality Management System standard specifically designed for organizations in the medical device industry, covering the full lifecycle of medical devices from design and development through manufacturing, installation, and servicing. Unlike ISO 9001 which focuses on customer satisfaction, ISO 13485 emphasizes regulatory compliance and patient safety, imposing mandatory requirements for design controls, supplier qualification, risk management (linked to ISO 14971), sterility assurance, and post-market surveillance. Certification to ISO 13485 is required for EU CE marking (MDR 2017/745 and IVDR 2017/746), accepted by Health Canada, TGA, and NMPA, and recognized by the FDA as evidence of quality system compliance. AI-based Software as a Medical Device (AIaMD) developers must implement ISO 13485 to demonstrate that their development process meets regulatory quality expectations."
Technical ID
iso-13485-qms
ISO 14971 (Medical Risk)
"ISO 14971:2019 is the international standard for the application of risk management to medical devices. It provides a framework for manufacturers to identify hazards, estimate and evaluate risks, control these risks, and monitor the effectiveness of these controls throughout the entire product lifecycle."
Technical ID
iso-14971-medical-risk
ISO 15189 (Medical Labs)
"ISO 15189:2022 is the international standard for medical laboratories, specifying requirements for quality and competence. It addresses both the technical competence of the laboratory and its ability to deliver technically valid results, focusing on patient safety and the clinical utility of laboratory testing."
Technical ID
iso-15189-medical-labs
ISO 27799 (Health InfoSec)
"ISO 27799:2016 (Health informatics — Information security management in health using ISO/IEC 27002) is the primary standard for implementing ISO 27001 in healthcare. It provides specific guidance on the additional security controls and management practices needed to protect personal health information (PHI) within healthcare organizations and their suppliers."
Technical ID
iso-27799-health-info-sec
Considerations for Design, Development, and Analytical Validation of Next Generation Sequencing (NGS) – Based In Vitro Diagnostics (IVDs) Intended to Aid in the Diagnosis of Suspected Germline Diseases
"This guidance document describes one part of FDA’s efforts to create a flexible and adaptive regulatory approach to the oversight of next generation sequencing (NGS)-based tests. As a step toward this vision, FDA is outlining key considerations for designing, developing, and establishing analytical validity of NGS-based tests used for whole exome human DNA sequencing (WES) or targeted human DNA sequencing intended to aid in the diagnosis of symptomatic individuals with suspected germline diseases or other conditions. The term “germline diseases or other conditions” encompasses those genetic diseases or other conditions arising from inherited or de novo germline variants. The recommendations in this guidance are intended to both assist test developers directly, and also to inform the development of consensus standards by experts in the community. As a general principle, test developers should first define the indications for use statement of their test, as this determines how the test should perform. When defining appropriate test performance, developers should prospectively determine the types of studies that should be conducted (e.g., accuracy) as well as the thresholds that should be met for each study type. After design and development of the test, validation studies should indicate if the predefined performance is met. If the test does not meet any of the predefined performance thresholds, the test should be modified and revalidated."
Technical ID
ngs-ivds-germline-diseases
NHS Data Security and Protection Toolkit (DSPT)
"The NHS Data Security and Protection Toolkit (DSPT) is a mandatory annual self-assessment for all organizations with access to NHS patient data in England, measuring performance against the 10 National Data Guardian (NDG) data security standards to ensure information is handled securely."
Technical ID
nhs-data-security-protection-toolkit
Cybersecurity of Genomic Data
"This report describes current practices in cybersecurity and privacy risk management for protecting genomic data. Genomic data's unique characteristics, such as being immutable and containing information about kinship and health, raise cybersecurity and privacy concerns that are inadequately addressed with current policies, guidance, and technical controls. This document addresses challenges and concerns identified by bioeconomy stakeholders, including practices for data generation, safe and responsible data sharing, monitoring of processing systems, and the lack of specific guidance for genomic data processors. Gaps in the regulatory and policy landscape concerning national security and privacy threats from the collection, storage, and sharing of human genomic data are also highlighted. The report identifies that cyber attacks targeting genomic data can threaten national security, economic stability through intellectual property theft, and individual privacy. These attacks can disrupt biopharmaceutical output, agricultural production, and lead to the development of biological weapons or surveillance of citizens. The document proposes a set of solution ideas that address real-life use cases occurring at various stages of the genomic data lifecycle, including candidate mitigation strategies and their expected benefits, based on stakeholder input from workshops hosted by the National Cybersecurity Center of Excellence (NCCoE)."
Technical ID
nist-ir-8432-genomic-data
21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program (45 CFR Parts 170 and 171)
"This regulation prohibits practices likely to interfere with, prevent, or materially discourage the access, exchange, or use of electronic health information (EHI) by healthcare providers, health IT developers, and health information networks/exchanges, as defined in 45 CFR § 171.103. It mandates the adoption of standardized APIs, primarily FHIR, to facilitate secure and seamless data access for patients and other authorized parties."
Technical ID
us-21st-century-cures-act-2016
42 CFR Part 2 — Confidentiality of Substance Use Disorder Patient Records (2024 Final Rule)
"This regulation modifies the confidentiality rules for substance use disorder (SUD) patient records from federally assisted programs, primarily by permitting a single patient consent for all future uses and disclosures for treatment, payment, and health care operations (TPO), aligning Part 2 more closely with HIPAA. This key change, outlined in § 2.33, simplifies data sharing for care coordination while maintaining patient privacy protections."
Technical ID
us-42-cfr-part-2-2024
Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Interoperability and Patient Access for Medicare Advantage Organization and Medicaid Managed Care Plans, State Medicaid Agencies, CHIP Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges, and Health Care Providers
"This rule requires CMS-regulated payers to implement and maintain a secure, standards-based Patient Access API using HL7 FHIR Release 4, enabling patients to access their claims, encounter, and clinical data via third-party applications. This mandate, detailed in 42 CFR § 422.119, also includes provisions to prevent information blocking and enhance data exchange between payers."
Technical ID
us-cms-interoperability-rule-2020
Ethics and Governance of Artificial Intelligence for Health
"This World Health Organization guidance establishes six core principles for the ethical design, deployment, and governance of AI in the health sector, applicable to developers, regulators, and healthcare providers. It mandates that AI for health must protect human autonomy, promote well-being and safety, ensure transparency and intelligibility, foster responsibility and accountability, ensure inclusivity and equity, and be sustainable and responsive (Chapter 2)."
Technical ID
who-ethics-ai-health-2021
Technical Registry Export
Context: Medical & Healthcare / Total Filtered: 46 Nodes
This utility allows developers and AI architects to instantly extract technical identifiers for the current filtered view. Use these IDs to programmatically call the Bidda Sovereign Forest API. All exports respect the global Triple-Verification Pipeline.